Jolkinolide B Ameliorates Liver Inflammation and Lipogenesis by Regulating JAK/STAT3 Pathway
Hepatic dysregulation of lipid metabolism exacerbates inflammation and enhances the progression of metabolic dysfunction-associated steatotic liver disease (MASLD). STAT3 has been linked to lipid metabolism and inflammation. Jolkinolide B (JB), derived from , is known for its pharmacological anti-in...
Gespeichert in:
| Veröffentlicht in: | Biomolecules & therapeutics 2024-11, Vol.32 (6), p.793-800 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 800 |
|---|---|
| container_issue | 6 |
| container_start_page | 793 |
| container_title | Biomolecules & therapeutics |
| container_volume | 32 |
| creator | Noh, Hye-Rin Sui, Guoyan Lee, Jin Woo Wang, Feng Park, Jeong-Su Ma, Yuanqiang Ma, Hwan Jeong, Ji-Won Shin, Dong-Su Wu, Xuefeng Hwang, Bang-Yeon Roh, Yoon Seok |
| description | Hepatic dysregulation of lipid metabolism exacerbates inflammation and enhances the progression of metabolic dysfunction-associated steatotic liver disease (MASLD). STAT3 has been linked to lipid metabolism and inflammation. Jolkinolide B (JB), derived from
, is known for its pharmacological anti-inflammatory and anti-tumor properties. Therefore, this study investigated whether JB affects MASLD prevention by regulating STAT3 signaling. JB attenuated steatosis and inflammatory responses in palmitic acid (PA)-treated hepatocytes. Additionally, JB treatment reduced the mRNA expression of
lipogenic genes, such as acetyl-CoA carboxylase and stearoyl-CoA desaturase 1. Interestingly, JB-mediated reduction in inflammation and lipogenesis was dependent on STAT3 signaling. JB consistently modulated mitochondrial dysfunction and the mRNA expression of inflammatory cytokines by inhibiting PA-induced JAK/STAT3 activation. This study suggests that JB is a potential therapeutic agent to prevent major stages of MASLD through inhibition of JAK/STAT3 signaling in hepatocytes. |
| doi_str_mv | 10.4062/biomolther.2024.033 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11535294</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3113748477</sourcerecordid><originalsourceid>FETCH-LOGICAL-c286t-2ec2ebb423c9b80cebf46ece7d62af03f68ebf9a1dec44858a07cb483f584fe83</originalsourceid><addsrcrecordid>eNpVkU9vEzEQxa0K1Kaln6BS5SOXTf1v194TChWUlkggCDcky-udTdx67WBvivLtcdXSwmmkeW_ezOiH0Bklc0EadtG5OEY_bSDNGWFiTjg_QDNGSF0JofgrNKOtbKqWCnWEjnO-JaSRtG4O0RFvuSSSkxn6eRP9nQvRux7we7wYwbuYzAQZL909JHwdBm_G0UwuBmxCX9rbuIYA2WXc7fE3WO98UcMa3yw-X3xfLVYcfzXT5rfZv0GvB-MznD7VE_Tj44fV5adq-eXq-nKxrCxTzVQxsAy6TjBu204RC90gGrAg-4aZgfChUaXVGtqDLZ_VyhBpu_LiUCsxgOIn6N1j7nbXjdBbCFMyXm-TG03a62ic_l8JbqPX8V5TWvOataIkvH1KSPHXDvKkR5cteG8CxF3WnFIuhRJSFit_tNoUc04wPO-hRD-A0S9g9AMYXcCUqfN_T3ye-UuC_wFj-I7-</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3113748477</pqid></control><display><type>article</type><title>Jolkinolide B Ameliorates Liver Inflammation and Lipogenesis by Regulating JAK/STAT3 Pathway</title><source>KoreaMed Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Noh, Hye-Rin ; Sui, Guoyan ; Lee, Jin Woo ; Wang, Feng ; Park, Jeong-Su ; Ma, Yuanqiang ; Ma, Hwan ; Jeong, Ji-Won ; Shin, Dong-Su ; Wu, Xuefeng ; Hwang, Bang-Yeon ; Roh, Yoon Seok</creator><creatorcontrib>Noh, Hye-Rin ; Sui, Guoyan ; Lee, Jin Woo ; Wang, Feng ; Park, Jeong-Su ; Ma, Yuanqiang ; Ma, Hwan ; Jeong, Ji-Won ; Shin, Dong-Su ; Wu, Xuefeng ; Hwang, Bang-Yeon ; Roh, Yoon Seok</creatorcontrib><description>Hepatic dysregulation of lipid metabolism exacerbates inflammation and enhances the progression of metabolic dysfunction-associated steatotic liver disease (MASLD). STAT3 has been linked to lipid metabolism and inflammation. Jolkinolide B (JB), derived from
, is known for its pharmacological anti-inflammatory and anti-tumor properties. Therefore, this study investigated whether JB affects MASLD prevention by regulating STAT3 signaling. JB attenuated steatosis and inflammatory responses in palmitic acid (PA)-treated hepatocytes. Additionally, JB treatment reduced the mRNA expression of
lipogenic genes, such as acetyl-CoA carboxylase and stearoyl-CoA desaturase 1. Interestingly, JB-mediated reduction in inflammation and lipogenesis was dependent on STAT3 signaling. JB consistently modulated mitochondrial dysfunction and the mRNA expression of inflammatory cytokines by inhibiting PA-induced JAK/STAT3 activation. This study suggests that JB is a potential therapeutic agent to prevent major stages of MASLD through inhibition of JAK/STAT3 signaling in hepatocytes.</description><identifier>ISSN: 1976-9148</identifier><identifier>EISSN: 2005-4483</identifier><identifier>DOI: 10.4062/biomolther.2024.033</identifier><identifier>PMID: 39370730</identifier><language>eng</language><publisher>Korea (South): The Korean Society of Applied Pharmacology</publisher><subject>Original</subject><ispartof>Biomolecules & therapeutics, 2024-11, Vol.32 (6), p.793-800</ispartof><rights>Copyright © 2024, The Korean Society of Applied Pharmacology 2024</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c286t-2ec2ebb423c9b80cebf46ece7d62af03f68ebf9a1dec44858a07cb483f584fe83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11535294/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11535294/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39370730$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Noh, Hye-Rin</creatorcontrib><creatorcontrib>Sui, Guoyan</creatorcontrib><creatorcontrib>Lee, Jin Woo</creatorcontrib><creatorcontrib>Wang, Feng</creatorcontrib><creatorcontrib>Park, Jeong-Su</creatorcontrib><creatorcontrib>Ma, Yuanqiang</creatorcontrib><creatorcontrib>Ma, Hwan</creatorcontrib><creatorcontrib>Jeong, Ji-Won</creatorcontrib><creatorcontrib>Shin, Dong-Su</creatorcontrib><creatorcontrib>Wu, Xuefeng</creatorcontrib><creatorcontrib>Hwang, Bang-Yeon</creatorcontrib><creatorcontrib>Roh, Yoon Seok</creatorcontrib><title>Jolkinolide B Ameliorates Liver Inflammation and Lipogenesis by Regulating JAK/STAT3 Pathway</title><title>Biomolecules & therapeutics</title><addtitle>Biomol Ther (Seoul)</addtitle><description>Hepatic dysregulation of lipid metabolism exacerbates inflammation and enhances the progression of metabolic dysfunction-associated steatotic liver disease (MASLD). STAT3 has been linked to lipid metabolism and inflammation. Jolkinolide B (JB), derived from
, is known for its pharmacological anti-inflammatory and anti-tumor properties. Therefore, this study investigated whether JB affects MASLD prevention by regulating STAT3 signaling. JB attenuated steatosis and inflammatory responses in palmitic acid (PA)-treated hepatocytes. Additionally, JB treatment reduced the mRNA expression of
lipogenic genes, such as acetyl-CoA carboxylase and stearoyl-CoA desaturase 1. Interestingly, JB-mediated reduction in inflammation and lipogenesis was dependent on STAT3 signaling. JB consistently modulated mitochondrial dysfunction and the mRNA expression of inflammatory cytokines by inhibiting PA-induced JAK/STAT3 activation. This study suggests that JB is a potential therapeutic agent to prevent major stages of MASLD through inhibition of JAK/STAT3 signaling in hepatocytes.</description><subject>Original</subject><issn>1976-9148</issn><issn>2005-4483</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpVkU9vEzEQxa0K1Kaln6BS5SOXTf1v194TChWUlkggCDcky-udTdx67WBvivLtcdXSwmmkeW_ezOiH0Bklc0EadtG5OEY_bSDNGWFiTjg_QDNGSF0JofgrNKOtbKqWCnWEjnO-JaSRtG4O0RFvuSSSkxn6eRP9nQvRux7we7wYwbuYzAQZL909JHwdBm_G0UwuBmxCX9rbuIYA2WXc7fE3WO98UcMa3yw-X3xfLVYcfzXT5rfZv0GvB-MznD7VE_Tj44fV5adq-eXq-nKxrCxTzVQxsAy6TjBu204RC90gGrAg-4aZgfChUaXVGtqDLZ_VyhBpu_LiUCsxgOIn6N1j7nbXjdBbCFMyXm-TG03a62ic_l8JbqPX8V5TWvOataIkvH1KSPHXDvKkR5cteG8CxF3WnFIuhRJSFit_tNoUc04wPO-hRD-A0S9g9AMYXcCUqfN_T3ye-UuC_wFj-I7-</recordid><startdate>20241101</startdate><enddate>20241101</enddate><creator>Noh, Hye-Rin</creator><creator>Sui, Guoyan</creator><creator>Lee, Jin Woo</creator><creator>Wang, Feng</creator><creator>Park, Jeong-Su</creator><creator>Ma, Yuanqiang</creator><creator>Ma, Hwan</creator><creator>Jeong, Ji-Won</creator><creator>Shin, Dong-Su</creator><creator>Wu, Xuefeng</creator><creator>Hwang, Bang-Yeon</creator><creator>Roh, Yoon Seok</creator><general>The Korean Society of Applied Pharmacology</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20241101</creationdate><title>Jolkinolide B Ameliorates Liver Inflammation and Lipogenesis by Regulating JAK/STAT3 Pathway</title><author>Noh, Hye-Rin ; Sui, Guoyan ; Lee, Jin Woo ; Wang, Feng ; Park, Jeong-Su ; Ma, Yuanqiang ; Ma, Hwan ; Jeong, Ji-Won ; Shin, Dong-Su ; Wu, Xuefeng ; Hwang, Bang-Yeon ; Roh, Yoon Seok</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c286t-2ec2ebb423c9b80cebf46ece7d62af03f68ebf9a1dec44858a07cb483f584fe83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Original</topic><toplevel>online_resources</toplevel><creatorcontrib>Noh, Hye-Rin</creatorcontrib><creatorcontrib>Sui, Guoyan</creatorcontrib><creatorcontrib>Lee, Jin Woo</creatorcontrib><creatorcontrib>Wang, Feng</creatorcontrib><creatorcontrib>Park, Jeong-Su</creatorcontrib><creatorcontrib>Ma, Yuanqiang</creatorcontrib><creatorcontrib>Ma, Hwan</creatorcontrib><creatorcontrib>Jeong, Ji-Won</creatorcontrib><creatorcontrib>Shin, Dong-Su</creatorcontrib><creatorcontrib>Wu, Xuefeng</creatorcontrib><creatorcontrib>Hwang, Bang-Yeon</creatorcontrib><creatorcontrib>Roh, Yoon Seok</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Biomolecules & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Noh, Hye-Rin</au><au>Sui, Guoyan</au><au>Lee, Jin Woo</au><au>Wang, Feng</au><au>Park, Jeong-Su</au><au>Ma, Yuanqiang</au><au>Ma, Hwan</au><au>Jeong, Ji-Won</au><au>Shin, Dong-Su</au><au>Wu, Xuefeng</au><au>Hwang, Bang-Yeon</au><au>Roh, Yoon Seok</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Jolkinolide B Ameliorates Liver Inflammation and Lipogenesis by Regulating JAK/STAT3 Pathway</atitle><jtitle>Biomolecules & therapeutics</jtitle><addtitle>Biomol Ther (Seoul)</addtitle><date>2024-11-01</date><risdate>2024</risdate><volume>32</volume><issue>6</issue><spage>793</spage><epage>800</epage><pages>793-800</pages><issn>1976-9148</issn><eissn>2005-4483</eissn><abstract>Hepatic dysregulation of lipid metabolism exacerbates inflammation and enhances the progression of metabolic dysfunction-associated steatotic liver disease (MASLD). STAT3 has been linked to lipid metabolism and inflammation. Jolkinolide B (JB), derived from
, is known for its pharmacological anti-inflammatory and anti-tumor properties. Therefore, this study investigated whether JB affects MASLD prevention by regulating STAT3 signaling. JB attenuated steatosis and inflammatory responses in palmitic acid (PA)-treated hepatocytes. Additionally, JB treatment reduced the mRNA expression of
lipogenic genes, such as acetyl-CoA carboxylase and stearoyl-CoA desaturase 1. Interestingly, JB-mediated reduction in inflammation and lipogenesis was dependent on STAT3 signaling. JB consistently modulated mitochondrial dysfunction and the mRNA expression of inflammatory cytokines by inhibiting PA-induced JAK/STAT3 activation. This study suggests that JB is a potential therapeutic agent to prevent major stages of MASLD through inhibition of JAK/STAT3 signaling in hepatocytes.</abstract><cop>Korea (South)</cop><pub>The Korean Society of Applied Pharmacology</pub><pmid>39370730</pmid><doi>10.4062/biomolther.2024.033</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1976-9148 |
| ispartof | Biomolecules & therapeutics, 2024-11, Vol.32 (6), p.793-800 |
| issn | 1976-9148 2005-4483 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11535294 |
| source | KoreaMed Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access |
| subjects | Original |
| title | Jolkinolide B Ameliorates Liver Inflammation and Lipogenesis by Regulating JAK/STAT3 Pathway |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T11%3A36%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Jolkinolide%20B%20Ameliorates%20Liver%20Inflammation%20and%20Lipogenesis%20by%20Regulating%20JAK/STAT3%20Pathway&rft.jtitle=Biomolecules%20&%20therapeutics&rft.au=Noh,%20Hye-Rin&rft.date=2024-11-01&rft.volume=32&rft.issue=6&rft.spage=793&rft.epage=800&rft.pages=793-800&rft.issn=1976-9148&rft.eissn=2005-4483&rft_id=info:doi/10.4062/biomolther.2024.033&rft_dat=%3Cproquest_pubme%3E3113748477%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3113748477&rft_id=info:pmid/39370730&rfr_iscdi=true |